|
|
|
| Effect of Paclitaxel Combined with Cisplatin Intraperitoneal Circulation Thermoperfusion Chemotherapy on Tumor Markers and Prognosis in Patients with Ovarian Cancer |
| CUI Hong-jun, XIN Xiao-sen, ZHANG Shu-ze, et al |
| Department of Oncology and Hematology, Shandong Provincial Third Hospital,Jinan Shandong 250000 |
|
|
|
|
Abstract 【Objective】To investigate the effect of paclitaxel combined with cisplatin intraperitoneal thermal perfusion chemotherapy on tumor markers and prognosis in patients with ovarian cancer.【Methods】80 women diagnosed with ovarian cancer in our hospital were randomly divided into observation group and control group, with 40 cases in each group. The control group was treated with paclitaxel combined with cisplatin intravenous drip, and the observation group was treated with paclitaxel combined with cisplatin intraperitoneal circulation thermal perfusion. The curative effects of the two groups after 4 months of treatment were compared; The levels of serum carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), neuron specific enolase (NSE), carbohydrate antigen 125 (CA125) and kappa functional state score (KPS) were evaluated and compared between the two groups before and after treatment; The long-term survival and adverse reactions of the two groups were compared.【Results】the objective remission rate (ORR) in the observation group was 80.00% (32/40), which was significantly higher than 57.50% (23/40) in the control group (P<0.05). CEA, NSE and CA125 in the observation group were significantly lower than those before treatment and after treatment in the control group, and KPS scores were significantly higher than those before treatment and after treatment in the control group (P<0.05). The 1-year survival rate in the observation group was significantly higher than that in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 80.00% (32/40), and there was no significant difference compared with 67.50% (27/40) in the control group (P>0.05).【Conclusion】Paclitaxel combined with cisplatin for intraperitoneal circulation thermal perfusion is more effective and safe, and has a positive impact on improving the prognosis of patients.
|
|
Received: 12 July 2021
|
|
|
|
|
|
[1] AVERETTE H E, JANICEK M F, MENCK H R. The national cancer data base report on ovarian cancer[J].Cancer,1995, 76(6):1096-1103.
[2] BOLIS G, VILLA A, GUAMERIO P, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy[J].Cancer,1996,77(1):128-131.
[3] 王强, 张宇涛, 孙静,等. 紫杉醇联合顺铂治疗进展期卵巢癌临床疗效观察[J].中国药物与临床, 2017, 17(9):1334-1335.
[4] 孙明月. 吉西他滨联合腹腔热灌注化疗治疗晚期胰腺癌疗效观察[J].医学临床研究, 2014, 31(12):2377-2378.
[5] 谢幸, 苟文丽. 妇产科学[M].第8版.北京:人民卫生出版社, 2013:321-328.
[6] 丁婕, 戴旭, 孟宪运,等. 实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复, 2015, 22(9):1150-1152.
[7] 徐粤. 中药结合TP化疗方案对晚期卵巢癌患者生存质量的影响#[J].中国医药导刊, 2016, 18(11):1144-1145.
[8] 闫玉兰, 张冬梅, 王英,等. 腹腔灌注与静脉化疗治疗晚期卵巢癌的疗效对比研究[J].国际妇产科学杂志, 2014, 41(6):655-657.
[9] 叶冬云. 紫杉醇联合顺铂腹腔热灌注化疗治疗晚期卵巢癌的疗效观察[J].临床和实验医学杂志, 2014, 14(10):838-840.
[10] 李宁, 田永巍, 高岭,等. 卵巢癌恶性腹腔积液TP方案静脉联合循环热灌注化疗临床疗效分析[J].中华肿瘤防治杂志, 2017, 24(2):119-123.
[11] 吴蕴瑜, 陈历排, 赵营,等. 紫杉醇联合顺铂循环式腹腔热灌注化疗对卵巢癌疗效和安全性分析[J].肿瘤药学, 2016, 6(4):291-295.
[12] 易成文, 朱培霞, 董志成. 紫杉醇和顺铂腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效与安全性研究[J].实用癌症杂志, 2018, 33(11):65-68. |
|
|
|
2021, Vol. 38 
